HIV Superinfection in Kidney Transplant Recipients With HIV Who Received Organs From Donors With HIV
- PMID: 40439124
- PMCID: PMC12349943
- DOI: 10.1093/infdis/jiaf284
HIV Superinfection in Kidney Transplant Recipients With HIV Who Received Organs From Donors With HIV
Abstract
Transplantation of kidneys from donors with HIV to recipients with HIV (HIV D+/R+) has been shown to be safe and effective, but there is a unique risk of donor-derived HIV superinfection (HIV-SI) in these recipients. Recipients from a multicenter observational HIV D+/R+ study were examined for HIV-SI by site-directed next-generation sequencing (Illumina). Eighteen recipients of HIV D+/R+ kidney transplants had baseline and follow-up samples that successfully amplified. One recipient was confirmed to have experienced donor-derived HIV-SI at week 26 but did not experience any clinically significant changes. HIV-SI in recipients of HIV D+/R+ transplants is rare, and the clinical ramifications appear negligible.
Keywords: HIV; HOPE Act; kidney; organ transplantation; superinfection.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest. Outside the current work, C. M. D. received payment for serving on a grant review committee for Gilead Sciences, and Gilead Sciences donates drug products to 2 studies on which C. M. D. is an investigator. Outside the current work, J. H. reports research support from Pfizer, Janssen, Ferring, Scynexis, AstraZeneca, and the Antibiotic Resistance Leadership Group; a leadership role at the Louisiana Organ Procurement Agency; and payments from Pfizer, AstraZeneca, Innoviva, and the Antibiotic Resistance Leadership Group. D. L. S. received payment as a journal editor for Springer; consulting fees from AstraZeneca, CareDx, Moderna Therapeutics, Medscape, Novavax, Regeneron, Springer Publishing, Hansa, and Roche; and honorarium for AstraZeneca, CareDx, Houston Methodist, Northwell Health, Optum Health Education, Sanofi, WebMd, and ASN. C. A. Q. S. received payment from UpToDate, Inc. J. S. reports research support from F2G, Merck, and Moderna; has received consulting fees from MedCure and OneLegacy; has received honoraria from Viracor/Eurofins; has received support for attending meetings and travel from the International Society for Heart and Lung Transplantation; and serves a leadership role in the American Society for Transplantation Working Group on Older Patients. All other authors report no potential conflicts.
References
-
- Wearne N, Davidson B. HIV-associated kidney disease: the changing spectrum and treatment priorities. Curr Opin Nephrol Hypertens 2024; 33:603–12. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical